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Abstract: Background. Factors determining the individual
susceptibility to head and neck squamous cell carcinoma
(HNSCC) are still largely unknown. An imbalance between en-
zymes involved in the toxification and detoxification of (pre)-
carcinogens closely related to HNSCC, which may appear during
smoking and alcohol consumption, may play a role. Genetic poly-
morphisms in glutathione S-transferases (GSTs) often result in
altered detoxification, which may contribute to individual suscep-
tibility to HNSCC.
Methods. We studied the frequencies of polymorphic variants
in the GSTP1 gene in 235 patients with HNSCC and 285 healthy
controls. In addition, data on exposure to alcohol and tobacco
consumption were recorded. DNA was extracted from whole
blood, and polymerase chain reaction–based methods were used
to detect genetic polymorphisms.
Results. In patients with HNSCC and control groups, the ho-
mozygous GSTP1 BB genotype was observed in 12.3% and
13.6%, respectively. No statistical differences were found for the
GSTP1 AA and GSTP1 AB/GSTP1BB genotypes.
Conclusions. Our study showed that genetic polymorphisms
of GSTP1 are not associated with altered susceptibility to
HNSCC. © 2002 Wiley Periodicals, Inc. Head Neck 25: 37–
43, 2003
Keywords: head and neck cancer; glutathione S-transferase P1;
phase II enzyme; genetic polymorphism
An imbalance in phase I drug metabolism en-
zymes, such as cytochromes P450 (CYPs), or
phase II detoxification enzymes, such as glutathi-
one S-transferases (GSTs), may contribute to the
individual susceptibility to head and neck squa-
mous cell carcinoma (HNSCC). These enzymes,
for instance, are involved in the toxification and
detoxification of metabolites of polycyclic aro-
matic hydrocarbons (PAHs), one of the primary
carcinogens of tobacco smoke.1 Most PAHs first
require activation by phase I enzymes to become
potential carcinogens that are subsequently de-
toxified by phase II enzymes.
Correspondence to: M. B. Oude Ophuis
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As a result of conjugation with glutathione,
the potential carcinogens are eliminated, and
DNA or other important biomolecules are pro-
tected against damage or adduct formation.2–5 In
humans, the GST enzymes can be divided into
five main classes: Alpha (GSTA), Mu (GSTM), Pi
(GSTP), Theta (GSTT), and Zeta (GSTZ). Each
class consists of one or more isoenzymes with dif-
ferent, but sometimes overlapping, substrate
specificity.4,5 At present, genetic polymorphisms
have been demonstrated for GSTM1, GSTT1, and
GSTP1.5–9
Polymorphisms in the GSTP1 gene consist of
the variant genotypes GSTP1 AB and GSTP1 BB
next to the wild-type GSTP1 AA. The frequency of
GSTP1 AA in healthy controls ranges from 42%–
69%.9–14 A transition of adenine (A) to guanine
(G) at nucleotide 313 in exon 5 of the GSTP1 gene
results in substitution of isoleucine (Ile) to valine
(Val) at position 104 in the amino acid sequence of
the protein.7,15,16 The valine variants exhibit
lower specific activity and affinity for the electro-
philic substrates of the enzyme.7,13,15 The valine-
containing homozygous variant, GSTP1 BB, oc-
curs in approximately 10% of healthy controls,
whereas the heterozygous Ile-Val variant, GSTP1
AB, occurs in approximately 35% of controls.9–14
The GSTP1 gene encodes for the isoenzyme
GSTP1-1. The GSTP1-1 enzyme level has been
extensively studied in relation to tobacco-
associated malignancies. The GSTP1-1 enzyme is
overexpressed in many preneoplastic and neo-
plastic lesions. Elevated tissue levels of GSTP1-1
enzyme have been found in stomach, colorectal,
bladder, oral, pharynx, larynx, lung, skin, and
breast tumors compared with normal tissues of
matched controls.5,17–22 The GSTP1-1 enzyme
may be involved in the resistance to chemothera-
peutic agents and radiotherapy.5,23–25 Because
GSTP1-1 is also involved in the metabolism and
subsequent removal of anticancer drugs, high lev-
els of GSTP1-1 in tumors may contribute to drug
resistance in several different cancers.26–28 How-
ever, there are also contradictory reports.
Because the amino acid changes are the result
of the polymorphisms close to the area of hydro-
phobic binding site for electrophiles, the homozy-
gous GSTP1 BB and heterozygous GSTP1 AB
gene products result in a decreased specific activ-
ity and affinity for electrophilic compounds.7
Thus, the altered metabolic activity of these en-
zymes could influence susceptibility to head and
neck cancer. Earlier we investigated the possible
involvement in HNSCC and in benign head and
neck lesions of genetic polymorphisms in
CYP1A1, GSTM1, and GSTT1, but we found no
enhanced rates of GST null genotypes in the can-
cer population.29 Earlier work from our group
showed that the GSTP1-1 enzyme, in a quantita-
tive sense, is by far the most important detoxifi-
cation enzyme in human head and neck tissues.30
Therefore, we investigated genetic polymor-
phisms in GSTP1 in a large series of patients
with HNSCC and in matched healthy controls.
We also evaluated exposure to alcohol and tobacco
of these subjects and evaluated the potential ef-
fect modification between GSTP1 polymorphisms
and these environmental exposures.
MATERIALS AND METHODS
Patients and Controls. This case-control study
was conducted in the patient referral region of
Maastricht University Hospital. A total of 235
Caucasian patients (185 men, 50 women) with
primary HNSCC were recruited during their
scheduled admission at the Department of Oto-
laryngology, Head and Neck Surgery of the Maas-
tricht University Hospital between 1994–1998
(mean age 59.1 years; range, 23–86 years). This
group consists of 100 patients with laryngeal car-
cinoma (mean age, 59.9 years; range, 35–85
years), 114 patients with oral cavity/oropharyn-
geal carcinoma (mean age, 58.0 years; range, 23–
86 years), and a group of 21 patients (mean age,
61.4 years; range, 41–82 years) with hypopharyn-
geal carcinoma.
From the same base population, a group of 285
healthy Caucasian blood donors (199 men, 86
women) were recruited at the Blood Transfusion
Centre Limburg and served as a control group,
frequency matched on age in 10-year age groups
(mean age, 50 years; range, 19–91). The investi-
gations were approved by the Medical Ethical Re-
view Committee of the Academic Hospital of the
University of Maastricht, and informed consent
was obtained from all patients and controls ac-
cording to the Helsinki Declaration II (1975, re-
vised 1983).
Exposure Assessment, Blood Sampling, and Assess-
ment of Genetic Polymorphisms. Information on
tobacco use and alcohol consumption was col-
lected for all patients and controls by interview.
The amount of pack years (PY) was calculated as
the number of years smoking × the number of
packs a day (assuming 20 cigarettes  1 pack).
Never smokers were defined as subjects who had
smoked less than 1 pack year cumulatively.
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Blood was collected by venapuncture in sterile
siliconized EDTA K3 (15%) 4-mL Vacutainer
tubes (Becton Dickinson, San Jose, CA). Immedi-
ately after collection, whole blood was stored at
−20°C until use. Genomic DNA was isolated from
whole blood using the Wizard genomic DNA pu-
rification kit, according to the instructions of the
manufacturer (Promega, Madison, WI).
Genetic polymorphisms were detected by poly-
merase chain reaction-restriction fragment
length polymorphism (PCR-RFLP). For studying
the genetic polymorphism in GSTP1, a primer set
(105F and 105R) was designed so that the pres-
ence of the A to G substitution at codon 313 re-
sulted in the appearance of an Alw261 restriction
enzyme site.9 All primers were synthesized by
Life Technologies (Breda, The Netherlands). All
chemicals needed for PCR were purchased from
Promega (Madison, WI).
Statistical Analysis. The statistical program
SPSS 8.0 for Windows was used. Information on
GSTP1 genotype, smoking, or alcohol was miss-
ing in 0, 0, and 11 of the cases and 0, 3, and 1 of
controls, respectively. For the purpose of the
analysis, the PY of cigarette smoking were cat-
egorized as 0, 1–20, 21–40, 41–60, and 60+ PY or
in increments of 10 PY. Alcohol consumption was
categorized as 0–9, 10–50, and 51+ g/ day. Be-
cause there were only three subjects who indi-
cated never to have consumed alcohol, the first
category consists of 0–9 g/day. Analyses were con-
ducted for the total group of patients with
HNSCC, as well as for oral cavity/oropharyngeal
and laryngeal carcinoma separately. Because of
small numbers of hypopharyngeal carcinoma,
this group was not evaluated separately.
The association between GSTP1 polymor-
phisms, smoking, alcohol, and HNSCC was mod-
eled through multivariate logistic regression
analysis, controlling for age and gender. First,
analyses were conducted to examine the associa-
tions between GSTP1 genotype and HNSCC, con-
trolling for age, gender, smoking, and alcohol.
Specifically, we evaluated whether subjects with
GSTP1 AA are less susceptible to HNSCC than
those with GSTP1 AB/BB. Likewise associations
between smoking and HNSCC or alcohol con-
sumption and HNSCC were examined, control-
ling for age, gender, and alcohol or smoking, re-
spectively. The strength of the associations was
estimated as odds ratios combined with 95% con-
fidence intervals. Subsequently, logistic regres-
sion analyses were performed in which the asso-
ciation between smoking or alcohol and HNSCC
(and its subgroups) was evaluated within sub-
groups of the GSTP1 genotype, the wild-type
GSTP1 AA group, and the combined heterozy-
gote/homozygote GSTP1 AB/BB group. Likeli-
hood ratio tests were conducted to test statistical
significance of regression model terms, as well as
to test for trends and interactions. Two-sided p
values are reported throughout. Finally, the in-
teraction between smoking and alcohol was
evaluated, specifically within subgroups of the
GSTP1 genotype.
RESULTS
Table 1 shows the frequency analyses for the A to
G substitution at codon 313 in the GSTP1 gene,
which was examined in 235 HNSCC patients and
285 controls. The GSTP1 BB frequency is low in
the control group, as well as in the total HNSCC
group or its subgroups. To maintain values for
appropriate statistical analysis, we combined the
frequencies for GSTP1 AB and GSTP1 BB (Tables
3–5).In Table 2, the frequency distribution is
given on the smoking habits and the alcohol con-
Table 1. Frequency distribution of GSTP1 genotypes in
HNSCC cases and controls.
GSTP1
genotype
Controls
N (%)
All
HNSCC
cases
N (%)
Oral/oro-
pharynx
N (%)
Larynx
N (%)
AA 125 (43.9) 116 (49.4) 53 (46.5) 51 (51.0)
AB 121 (42.5) 90 (38.3) 48 (42.1) 36 (36.0)
BB 39 (13.6) 29 (12.3) 13 (11.4) 13 (13.0)
Total 285 235 114 100
Table 2. Frequency distribution of smoking and alcohol
consumption in HNSCC cases and controls.
Covariable
Controls
N (%)
All
HNSCC
cases
N (%)
Oral/oro-
pharynx
N (%)
Larynx
N (%)
Smoking pack years
0 86 (30.2) 13 (5.5) 7 (6.1) 3 (3.0)
1–20 130 (45.6) 36 (15.3) 20 (17.5) 13 (13.0)
21–40 60 (21.1) 113 (48.1) 52 (45.6) 53 (53.0)
41–60+ 9 (3.2) 73 (31.1) 35 (30.7) 31 (31.0)
Total 285 235 114 100
Alcohol g/day
0–9 139 (48.8) 18 (8.0) 7 (6.3) 10 (10.9)
10–50 142 (49.8) 106 (47.4) 44 (39.6) 54 (58.7)
51+ 3 (1.1) 100 (44.6) 60 (54.1) 28 (30.4)
Total 284 224 111 92
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sumption in HNSCC cases, subgroups of HNSCC,
and the control group. The HNSCC group in total,
as well as the two subgroups, show a significantly
higher tobacco exposure compared with the con-
trol group. The control group shows significantly
lower alcohol consumption than the HNSCC
cases (total or subgroups). In the oral/oropharyn-
geal subgroup, the rate of daily alcohol consump-
tion more than 51 g/day is much higher compared
with the laryngeal subgroup (54.1% vs 30.4%, re-
spectively). Alcohol consumption more than 51
g/day hardly exists in the control group.
Table 3 shows that the odds ratios (OR) for
alcohol or smoking are similar in the HNSCC
group as a total and the two subgroups, except for
alcohol consumption more than 51 g/day, when
there is a higher OR in the oral/oropharyngeal
group. To provide appropriate statistical values,
smoking is displayed with an increment of 10 PY.
When no adjustment is made for smoking and
alcohol (but only for age and gender), the OR for
GSTP1 AA vs GSTP1 AB/BB will be 1.31 in the
total HNSCC group.
The association between alcohol and smoking
Table 3. Association between alcohol, smoking, and GSTP1 genotype and HNSCC (total group of
cases and subgroups of oral/oropharyngeal and laryngeal cancer).
Risk factor
Total HNSCC
N = 235
OR (95% CI)
Oral/oropharynx
N = 114
OR (95% CI)
Larynx
N = 100
OR (95% CI)
Alcohol g/day
0–9 1.0* (ref) 1.0* (ref) 1.0* (ref)
10–50 5.36 (2.68–10.72) 8.23 (3.05–22.20) 5.00 (1.97–12.68)
51+ 194.16 (49.21–766.31) 420.03 (87.47–2016.92) 113.36 (22.91–560.84)
Test for trend, p value <.001 <.001 <.001
Smoking Pack years
Increment 10 PY 1.80† (1.51–2.14) 1.63† (1.34–1.97) 1.85† (1.51–2.26)
GSTP1 AB/BB 1.0‡ (ref) 1.0‡ (ref) 1.0‡ (ref)
GSTP1 AA 0.99 (0.58–1.71) 0.78 (0.38–1.60) 0.90 (0.46–1.79)
*Odds ratio, adjusted for age, gender, smoking, and GSTP1 genotype.
†Odds ratio, adjusted for age, gender, alcohol consumption, and GSTP1 genotype.
‡Odds ratio, adjusted for age, gender, alcohol consumption, and smoking.
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference value.
Table 4. Association between alcohol consumption, smoking, and HNSCC in subgroups of GSTP1 genotype.
Risk factor
Total HNSCC
OR (95% CI)
Oral/oropharynx
OR (95% CI)
Larynx
OR (95% CI)
Subgroup GSTP1 AA
(108 cases, 122 controls)
Alcohol g/day
0–9 1.0* (ref) 1.0* (ref) 1.0* (ref)
10–50 7.89 (2.75–22.68) 15.88 (2.66–94.66) 6.95 (1.76–27.50)
51+ 232.24 (38.22–1407.08) 696.88 (70.08–6930.15) 140.16 (16.22–1211.12)
Test for trend, p value <.001 <.001 <.001
Smoking pack years
Increment 10 PY 1.51† (1.21–1.80) 1.34† (1.10–1.80) 1.63† (1.21–1.97)
Subgroup GSTP1 AB/BB
(116 cases, 159 controls)
Alcohol g/day
0–9 1.0* (ref) 1.0* (ref) 1.0* (ref)
10–50 4.21 (1.65–10.70) 5.57 (1.64–18.89) 3.70 (1.07–12.84)
51+ 191.67 (20.88–1759.33) 307.88 (26.42–3588.09) 74.82 (6.76–828.31)
Test for trend, p value <.001 <.001 <.001
Smoking pack years
Increment 10 PY 2.28† (1.73–3.01) 2.41† (1.67–3.47) 2.46† (1.74–3.49)
*Adjusted for age, gender, smoking.
†Adjusted for age, gender, and alcohol.
Abbreviations: CI, confidence interval; OR, odds ratio; ref, reference value.
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and the GSTP1 polymorphisms is shown in Table
4. For oral/oropharyngeal cases with the GSTP1
AA genotype, alcohol consumption more than
doubles the OR compared with the GSTP1 AB/
BB genotype. This is also shown for laryngeal car-
cinoma. In the oral/oropharyngeal cases, as well
as the laryngeal cases with the GSTP1 AB/BB
genotype, odds ratios are increased by smoking
compared with the GSTP1 AA genotype. We
tested for interaction of alcohol consumption be-
tween subgroups of GSTP1 in the total HNSCC
group; LR-X  0.96, df  2, p > .05. Also the
interaction of smoking between subgroups of
GSTP1 in the total HNSCC group is calculated;
LR-X  6.04, df  1, p < .025.
In Table 5 we show a significant interaction
between smoking and alcohol consumption in
HNSCC susceptibility when not adjusted for
GSTP1 genotype. The effect of smoking is stron-
ger when more alcohol is consumed (OR increases
from 1.27 to 3.53). However, because of small
numbers (especially in high alcohol consumption
category), interaction between alcohol and smok-
ing and GSTP1 genotype cannot be fully calcu-
lated.
DISCUSSION
Glutathione S-transferases are involved in the de-
toxification of a wide variety of chemical carcino-
gens, including those derived from cigarette
smoke.5
The enzyme GSTP1-1 is known to catalyze the
detoxification of PAH in vitro and may be a major
enzyme involved in the detoxification of tobacco-
related metabolic products in vivo.5 The expres-
sion in tissues may vary, depending on site or
localization, and immunohistochemical studies
have shown a constant and widespread GSTP1-1
expression throughout pharyngeal and laryngeal
squamous cell epithelium in both normal and tu-
mor tissue.10 Earlier we showed that GSTP1-1 is
the most important GST enzyme in human head
and neck tissues.30 Therefore, we studied the oc-
currence of polymorphisms of this gene in pa-
tients with different head and neck tumors and
controls.
We previously reported that the GSTM1 and
GSTT1 null genotypes are not associated with an
increased susceptibility for HNSCC.29 In one of
the largest studies performed so far, we found no
significant association between risk of HNSCC
and occurrence of genetic polymorphisms in the
GSTP1 gene. This was also found for oral/
oropharyngeal cancers and laryngeal cancers
separately.
The GSTP1-1 enzyme is overexpressed in
many neoplastic lesions, such as malignancies of
stomach, colorectum, bladder, oral tissue, phar-
ynx, larynx, lung, skin, and breast compared with
corresponding normal tissues.5,17–22,30 However,
when estimating GSTP1-1 serum levels in pa-
tients with head and neck cancer, we found sig-
nificantly higher levels compared with controls,
but no association with GSTP1 genotype was ob-
served.31 This may strongly indicate that the
overexpression of GSTP1-1 in head and neck can-
cer is not dependent on genotype but most prob-
ably transcriptionally regulated.
We found a strong association between smok-
ing and alcohol consumption and HNSCC suscep-
tibility. Assessment of smoking or alcohol con-
sumption is difficult, especially with respect to
patient history for the total accumulative expo-
sure. Exposure usually takes place over many
years and is not always consistent. In addition,
different cigarette brands may yield completely
different nicotine and tar exposures. High con-
sumption of alcohol often is not revealed by pa-
tients because of its social unacceptance. It there-
Table 5. Interaction between alcohol and smoking regarding
risk of HNSCC in total group and in subgroups defined by
GSTP1 genotype.
Alcohol category
Smoking
OR (95% CI)
per 10
pack years
Total group
(224 cases, 281 controls)
Alcohol g/day
0–9 1.27 (1.03–1.57)
10–50 2.46 (1.90–3.20)
51+ 3.53 (1.27–9.81)
Test for interaction smoking/alcohol, 2 (p) 18.2 (p < .01)
Subgroup GSTP1 AA
(108 cases, 122 controls
Alcohol g/day
0–9 1.24 (0.96–1.60)
10–50 2.08 (1.44–3.01)
51+ np
Test for interaction smoking/alcohol, 2 (p) –
Subgroup GSTP1 AB/BB
(116 cases, 159 controls)
Alcohol g/day
0–9 1.43 (0.91–2.28)
10–50 2.85 (1.96–4.16)
51+ 0.57 (0.06–5.48)
Test for interaction smoking/alcohol, 2 (p) 3.5 (p > .05)
Abbreviations: CI, confidence interval; OR, odds ratio; np, no estimation
possible.
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fore would help to determine biomarkers such as
serum gamma-glutamyltransferase, which could
be indicative of recent consumption of alcohol. De-
velopment of biomarkers that could indicate the
exposure and the period of consumption would be
more helpful.
In our control population, GSTP1 BB occurs in
13.6% and GSTP1 AB in 42.5%. Our data for the
healthy controls are in agreement with the geno-
type frequencies in the control populations re-
ported by other researchers.9–14 Similar obser-
vations were found for the HNSCC group (12.3%
and 38.3%, respectively).
Our data for HNSCC patients are also in
agreement with several other studies performed.
Lin et al14 found that polymorphisms in GSTP1
were not associated with increased risk for esoph-
ageal cancer. They even found a slightly lower
occurrence of GSTP1 AB or BB genotypes in can-
cer and hyperplasia cases than in controls.14
Jourenkova-Mironova et al32 and Matthias et al10
found no association between the GSTP1 AB or
BB genotypes and risk of larynx cancer. Harries
et al9 reported an association between the occur-
rence of the GSTP1 polymorphism and suscepti-
bility to bladder or testicular cancer but found no
association with breast or colon cancer. In other
studies, no association was found between the
GSTP1 polymorphism and colorectal, lung, or
breast cancer.33,34
Several other studies, however, revealed a sig-
nificant correlation between occurrence of GSTP1
polymorphisms and preneoplastic and neoplastic
lesions. Lung cancer patients had a significant
higher frequency of GSTP1 BB genotype (15.9%)
and a lower frequency of GSTP1 AA genotype
(38.4%) than controls (9.1% and 51.5%, respec-
tively).12 Homozygous GSTP1 BB was found sig-
nificantly more often in patients with Barrett’s
esophagus and esophageal adenocarcinoma.35
Matthias et al10 reported that GSTP1 polymor-
phism influences susceptibility to pharyngeal but
not to laryngeal squamous cell carcinoma. How-
ever, when comparing our patient groups in a
similar way as Matthias et al10 (oral cavity/
oropharyngeal SCC and hypopharyngeal SCC
versus laryngeal SCC), we did not find a signifi-
cant difference in the genotype distributions. Ry-
berg et al12 reported that patients with the
GSTP1 BB genotype had higher DNA adduct lev-
els in lung tissue than the GSTP1 AA genotypes.
They also found a linear trend between DNA ad-
duct levels and occurrence rates of GSTP1 B al-
leles.
The variant genotypes GSTP1 AB and GSTP1
BB showed a different specific activity and affin-
ity for several electrophilic substrates but were
identical in their affinity for glutathione.7,15 The
properties of the variant genotypes were con-
ducted in “in vitro experiments” with recombi-
nant proteins by Ali Osman et al,7 which, how-
ever, does not necessarily provide adequate
information on the enzymes and their reactions
“in vivo.” In agreement with the in vitro results,
Watson et al13 and van Lieshout et al35 reported a
significantly lower conjugating activity with
1-chloro-2,4-dinitrobenzene (CDNB) in lung and
esophageal tissue samples, respectively, in pa-
tients with GSTP1 AB and GSTP1 BB compared
with GSTP1 AA genotypes.
In summary, we found no evidence for a pos-
sible genetic predisposition to HNSCC because of
genetic polymorphisms in the GSTP1 gene. This
suggests that the carcinogens involved in the eti-
ology of HNSCC may not be critically dependent
on detoxification by GSTP1-1. Further studies on
other combinations of polymorphic genotypes in
detoxification enzymes and their relation to local
and systemic enzyme concentration seem to be
justified.
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